

CALL FOR ABSTRACTS

www.asgct.org #ASGCT19



WASHINGTON HILTON

WASHINGTON, D.C. April 29 – May 2, 2019



SUBMIT YOUR ABSTRACT TO ASGCT AND PRESENT YOUR RESEARCH!




THE ASGCT 22ND ANNUAL MEETING IS THE PRIMARY FORUM FOR BRINGING TOGETHER SCIENTISTS, PHYSICIANS, PATIENT ADVOCATES, AND OTHER STAKEHOLDERS TO TRANSFORM THE PRACTICE OF MEDICINE BY ADVANCING GENE AND CELL THERAPIES TO ALLEVIATE HUMAN DISEASE.

WHY SHOULD YOU SUBMIT AN ABSTRACT TO ASGCT?

- Great opportunity to present and discuss your research with your peers and leaders in the gene and cell therapy field.
- **Free registration** for Associate Members who are the first and presenting author on an abstract.
- Awards and travel grants are given to approximately 150 abstract submitters based on abstract scores. Presentation and publication opportunities for accepted abstracts, with nearly 25% of submitted abstracts accepted for oral presentation.
- All accepted abstracts will be published in the online Supplement to the Society's journal, *Molecular Therapy*.

PREVIOUS MEETING ATTENDANCE

Attendance at the ASGCT Annual Meeting has risen dramatically over the past five years with attendance in 2018 nearly doubling from 2014.



AWARDS AND INCENTIVES

ASGCT IS PROUD TO OFFER **FREE REGISTRATION** TO THE ANNUAL MEETING FOR STUDENTS AND POSTDOCTORAL FELLOWS WHO ARE ASSOCIATE MEMBERS OF ASGCT AND THE FIRST AND PRESENTING AUTHOR OF AN ACCEPTED ABSTRACT!

MERITORIOUS ABSTRACT TRAVEL AWARDS

ASGCT supports the travel of approximately 150 Associate Members each year through the Meritorious Abstract Travel Award program. Awards are given out based on high abstract scores and recipients will receive a certificate and a travel reimbursement stipend of up to \$500 for domestic awardees and \$600 for international awardees.

EXCELLENCE IN RESEARCH AWARDS

The top ten to fifteen abstracts submitted by students and fellows will receive an Excellence in Research Award. Recipients will be announced at the end of the George Stamatoyannopoulos plenary lecture on Tuesday, April 30, 2019 and will receive a monetary award of \$500 along with a special plaque.

OUTSTANDING POSTER PRESENTATION AWARDS

The top poster presentations from each of the three poster sessions that occur during the ASGCT Annual Meeting are awarded Outstanding Poster Presentation Awards. Awardees are honored through notification to all meeting attendees and receive a special certificate for their contributions.

UNDERREPRESENTED MINORITY TRAVEL AWARDS

ASGCT will offer a limited number of Underrepresented Minority Travel Awards (\$500 value) to Associate Members submitting an abstract to the meeting. Eligible candidates must be a U.S. resident and self-identify as African American, Pacific Islander, Hispanic, or Native American.

POSTER FUNDING

Up to 30 Associate Members will receive funding (\$129 value) for their poster production. ASGCT will pay the cost for the poster production directly to the poster printing service.



ABSTRACT SUBMISSION INFORMATION

There is no fee to submit an abstract and free registration for the Annual Meeting will be given to Associate Members who are first and presenting author of an abstract. Approximately 25% of the abstracts submitted will be eligible for oral presentation based on the review scores. All accepted abstracts will be published in the May supplement to *Molecular Therapy*.

ELIGIBILITY

- ASGCT Members and non-Members are eligible to submit an abstract.
- Submitting an abstract does not register you for the meeting. You must register for the meeting to present your abstract.

INELIGIBILITY

- Papers that have been accepted for publication or published prior to the abstract submission deadline may not be submitted unless special consideration is requested.
- If your abstract was previously accepted for presentation at ASGCT or another national/international meeting, do not submit the abstract unless special permission is requested and granted from ASGCT.

INTERNATIONAL ABSTRACT SUBMITTERS

International abstract submitters who plan to attend the ASGCT 22nd Annual Meeting will need to apply for a VISA. The amount of time required to obtain a VISA has increased tremendously, so please apply early. Abstract submitters can generate invitation letters online at www.asgct.org/am19.

If you need assistance obtaining your letter of invitation, please contact Emily Hutmacher (ehutmacher@asgct.org) at the ASGCT Office.

ABSTRACT SUBMISSIONS OPEN:
OCTOBER 17, 2018

ABSTRACT SUBMISSIONS DEADLINE:
JANUARY 16, 2019 AT 11:59 PM CST.

TO SUBMIT YOUR ABSTRACT, PLEASE GO
TO **WWW.ASGCT.ORG/AM19**.

NOTIFICATION OF ABSTRACT ACCEPTANCE

Notification regarding acceptance of abstracts will be delivered via email on March 20, 2019. Meritorious Abstract Travel Awards, Excellence in Research Awards, and Underrepresented Minority Travel Awards acceptance and letters will also be sent at this time.

ACCEPTANCE OF PRESENTATION

All notified abstract presenters are required to accept their presentation as instructed in their notification email. This can be done online through the abstract submission site.

LATE BREAKING ABSTRACT SUBMISSIONS

ASGCT will not be accepting Late Breaking Abstract submissions for the 22nd Annual Meeting.

ABSTRACT QUESTIONS

For all questions regarding the abstract submission process, please contact Coe-Truman Technologies' Technical Support by phone at 1-217-398-1792 or by email at support@abstractsonline.com. If you would like to make changes to your abstract after submitting, you will now be able to return directly to your abstract and makes changes until the deadline.



ABSTRACT TOPIC CATEGORIES

WHEN SUBMITTING AN ABSTRACT, AUTHORS WILL **SELECT ONE FIRST CHOICE TOPIC AND ONE SECOND CHOICE TOPIC FROM THE LIST BELOW THAT BEST DESCRIBES THEIR ABSTRACT.**

A. Viral Vector Development

Includes regulation of gene expression. Vectors not specifically mentioned should be directed to the most closely related category. Hybrid vectors should be directed to the category that makes the largest contribution to the performance of the vector system.

- A1. RNA Virus Vectors
- A2. AAV Vectors
- A3. Adenovirus Vectors and Other DNA Viruses

B. Gene Targeting and Gene Correction

Basic development of novel technologies for genome editing, with or without site-specific endonuclease. Gene targeting projects focused on specific disease applications are strongly encouraged to submit abstracts to the suitable tissue/disease related category.

C. Oligonucleotide Therapeutics

Includes siRNAs, aptamers, antagomirs, miRNAs, shRNA, antisense, splice switching oligos, and plasmids.

D. Synthetic/Molecular Conjugates and Physical Methods for Delivery of Gene Therapeutics

Includes exosomes.

E. Disease Models and Clinical Applications

Includes inherited and acquired diseases, animal models, and clinical trials.

- E1. Metabolic, Storage, Endocrine, Liver and Gastrointestinal Diseases
- E2. Cardiovascular and Pulmonary Diseases
- E3. Neurologic Diseases (including Ophthalmic and Auditory Diseases)
- E4. Musculo-Skeletal Diseases
- E5. Cancer – Immunotherapy, Cancer Vaccines
- E6. Cancer – Oncolytic Viruses
- E7. Cancer – Targeted Gene and Cell Therapy
- E8. Hematologic and Immunologic Diseases

F. Immunological Aspects of Gene Therapy and Vaccines

Includes host responses and therapy/prevention of infectious diseases. Excludes cancer immunotherapy and cancer vaccines.

G. Cell Therapies

Includes development of somatic, embryonic and induced pluripotent stem cells or other therapeutic cell populations, and issues related to cell expansion or processing.

H. Clinical Translation of Gene and Cell Therapies

- H1. Vector and Cell Engineering, Production or Manufacturing
- H2. Pharmacology/Toxicology Studies or Assay Development

